Search company, investor...

Founded Year



Loan | IPO

Total Raised


About Osprey Medical

Osprey Medical is a company focused on the prevention of contrast-induced acute kidney injury (AKI) in the healthcare sector. The company's main product is a system that reduces the volume of contrast dye injected into patients during catheterization procedures, thereby lowering the risk of AKI without compromising the quality of imaging. The primary customers of Osprey Medical are healthcare providers in the cardiac catheterization field. It was founded in 2005 and is based in Hopkins, Minnesota.

Headquarters Location

5600 Rowland Road Suite 250

Hopkins, Minnesota, 55343,

United States




Expert Collections containing Osprey Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Osprey Medical is included in 1 Expert Collection, including Digital Health.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Osprey Medical Patents

Osprey Medical has filed 48 patents.

The 3 most popular patent topics include:

  • medical equipment
  • cardiac procedures
  • drug delivery devices
patents chart

Application Date

Grant Date


Related Topics




Acoustics, Vascular diseases, Medical equipment, Sound, Cardiac procedures


Application Date


Grant Date



Related Topics

Acoustics, Vascular diseases, Medical equipment, Sound, Cardiac procedures



Latest Osprey Medical News

Medical Imaging Reagent Market to Reach USD 464.17 Billion by 2032, Exhibiting 7% CAGR

Jul 7, 2023

News Provided By Share This Article Reports And Data The global Medical Imaging Reagent Market size was USD 252.48 billion in 2022, and is expected to reach a value of USD 464.17 billion in 2032, with a CAGR of 7% NEW YORK CITY, NY, UNITED STATES, July 7, 2023/ / -- The global Medical Imaging Reagent Market had a size of USD 252.48 billion in 2022. It is projected to reach USD 464.17 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7% during the forecast period. The growth of the market's revenue can be attributed to the increasing prevalence of chronic illnesses, the demand for non-invasive diagnostic treatments, and advancements in medical imaging techniques. Medical imaging reagents are chemical substances employed in imaging procedures to enhance the visibility of internal body features. These reagents encompass contrast agents, radiopharmaceuticals, and optical imaging agents. With the rising incidence of chronic diseases like cancer, cardiovascular disorders, and neurological conditions, the demand for medical imaging reagents is on the rise. These conditions are frequently diagnosed and monitored using medical imaging techniques such as computed tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and single-photon emission computed tomography (SPECT). Get Free Sample PDF (To Understand the Complete Structure of this Report [Summary + TOC]) @ The market for medical imaging reagents is expanding due to the growing preference for non-invasive diagnostic methods. Non-invasive techniques are favored due to their lower discomfort and reduced risks compared to invasive procedures. Medical imaging tools provide comprehensive information about internal body components without the need for surgery or other invasive treatments. Consequently, the utilization of medical imaging methods has increased, leading to a higher demand for the reagents employed in these procedures. Segments Covered in the Report – By Product Type Outlook- Strategic development: • GE Healthcare and Osprey Medical joined forces in 2021 to distribute Osprey's DyeVert contrast minimization device. This device is designed to reduce the amount of contrast used in imaging procedures, thereby enhancing patient safety. • In 2020, Bracco Imaging S.p.A. completed the acquisition of Blue Earth Diagnostics, a specialist in molecular imaging agents for cancer diagnosis. The acquisition, valued at $450 million, aimed to expand Bracco's product portfolio in the field of oncology. • Bayer Healthcare LLC made headlines in 2020 with its acquisition of Asklepios BioPharmaceutical, Inc., a company renowned for its expertise in gene therapy research and development. The acquisition, valued at $4 billion, aimed to bolster Bayer's presence in the gene therapy market. • In another strategic move in 2020, Guerbet SA announced a collaboration with IBM Watson Health. Their partnership aimed to develop an innovative artificial intelligence platform for medical imaging analysis. This platform harnesses the power of machine learning algorithms to enhance the accuracy and efficiency of medical imaging diagnoses. Competitive Landscape: • The global medical imaging reagent market features several key players, including Bracco Imaging S.p.A., GE Healthcare, Bayer Healthcare LLC, Mallinckrodt Pharmaceuticals, Lantheus Medical Imaging, Inc., Guerbet SA, Fujifilm Holdings Corporation, Siemens Healthineers, Koninklijke Philips N.V., PerkinElmer, Inc., and Thermo Fisher Scientific, Inc. • Bracco Imaging S.p.A. is a prominent player in the market. They focus on developing and distributing medical imaging products, including contrast agents and medical devices. The company has made strategic acquisitions, such as the purchase of Blue Earth Diagnostics in 2020, to expand their offerings in the field of oncology. • GE Healthcare is a renowned global provider of medical imaging and healthcare solutions. They offer a wide range of imaging products, including contrast agents and medical imaging devices. In 2021, GE Healthcare collaborated with Osprey Medical to distribute Osprey's DyeVert contrast minimization device, which improves patient safety by reducing the amount of contrast used during imaging procedures. • Bayer Healthcare LLC is a significant player in the medical imaging reagent market, with a focus on pharmaceuticals and life sciences. In 2020, they acquired Asklepios BioPharmaceutical, Inc., a company specializing in gene therapy research and development. This acquisition aimed to strengthen Bayer's position in the gene therapy market. • Mallinckrodt Pharmaceuticals, Lantheus Medical Imaging, Inc., Guerbet SA, Fujifilm Holdings Corporation, Siemens Healthineers, Koninklijke Philips N.V., PerkinElmer, Inc., and Thermo Fisher Scientific, Inc. are also notable players in the market, offering a variety of medical imaging reagents and related products. Request a customization of the report @ These companies play a crucial role in driving innovation, technological advancements, and research in the medical imaging reagent market, contributing to improved diagnostic capabilities and patient care. Browse for more reports: Hereditary Testing Market - Healthcare Patent Filing Outsourcing Market - Hangover Rehydration Supplements Market - John W.

Osprey Medical Frequently Asked Questions (FAQ)

  • When was Osprey Medical founded?

    Osprey Medical was founded in 2005.

  • Where is Osprey Medical's headquarters?

    Osprey Medical's headquarters is located at 5600 Rowland Road, Hopkins.

  • What is Osprey Medical's latest funding round?

    Osprey Medical's latest funding round is Loan.

  • How much did Osprey Medical raise?

    Osprey Medical raised a total of $6.5M.

  • Who are the investors of Osprey Medical?

    Investors of Osprey Medical include Paycheck Protection Program, CM Capital, Brandon Capital and Baker Heart and Diabetes Institute.

  • Who are Osprey Medical's competitors?

    Competitors of Osprey Medical include Preceptis Medical, Intuity Medical, Integrated Diagnostics, Accriva Diagnostics, CardioDx and 7 more.


Compare Osprey Medical to Competitors

MEC Dynamics

MEC Dynamics is a medical devices company developing and manufacturing point-of-care diagnostic products, using its proprietary technology. The company's devices have been designed for use in the both physician's office as well as the patient's home. They enable the 'real time' measurement of key blood analytes for early detection and more effective management of a variety of diseases including diabetes, cardiovascular diseases and cancer. Chronic and life-threatening diseases occurring in both industrial and developing countries could be better treated through early detection and proper monitoring. MEC aims to be a global developer and manufacturer of point-of-care diagnostic products using its technology platform. MEC's lead product, AvieA1c, is FDA 510K approved and NGSP certified.

Pelikan Technologies

Pelikan Technologies is dedicated to the development of hand-held diagnostic and monitoring devices capable of improving the screening and management of a variety of medical conditions. In addition to diabetes, the company's versatile technology platform has applications across a range of other medical conditions that involve blood screening and monitoring. Point-of-care testing and diagnostic panel test systems also represent markets that can benefit from Pelikan's technology. The Pelikan Sun can improve the quality of life for people with diabetes by combining several of the company's technologies into the most convenient and effective blood glucose self-monitoring device available. Pelikan's line of diabetes management tools will address the pain and inconvenience that has stymied the industry's manufacturers, and plagued people with diabetes, contributing to poor blood glucose monitoring compliance. By targeting these barr

Third Eye Diagnostics

Third Eye Diagnostics is a company focused on the development of non-invasive technologies for the evaluation of intracranial pressure, operating in the medical technology sector. The company's main product is a non-invasive intracranial pressure monitor that gathers information from the patient's eye, providing a single point reading of intracranial pressure, which can be used for diagnosing and monitoring conditions like traumatic brain injuries, stroke, and glaucoma. The company primarily sells to sectors such as hospital Neuro-ICUs, emergency rooms, surgical suites, medical transport vehicles, general practitioner offices, and sports events. It is based in Bethlehem, Pennsylvania.

Es Vascular

Es Vascular is a company focused on the medical industry, specifically in the distribution of medical supplies. The company offers a range of products including medical devices for urology, surgery, anesthesiology, tissue regeneration, wound management, biopsy needles, and gynecology. These products are designed to treat various medical conditions and assist in different medical procedures. It was founded in 2000 and is based in Israel.

Neuro Diagnostic Devices

Neuro Diagnostic Devices, also known as NeuroDx Development, is a medical device company operating in the healthcare sector. The company's primary product is a non-invasive device used to detect fluid flow in implanted cerebrospinal fluid (CSF) shunts, aiding in the diagnosis and treatment of neurosurgical conditions. The company primarily serves the healthcare industry, specifically the neurosurgical market. It is based in Yardley, Pennsylvania.


EyeSense develops an ophthalmic diagnostics system which can measure glucose levels without sampling blood. It is based on measuring the glucose in the interstitial fluid below the conjunctiva of the eye using a hand-held optical read-out device.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.